Pathstone Family Office’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $102K | Sell |
12,231
-4,628
| -27% | -$38.6K | ﹤0.01% | 1582 |
|
|
2023
Q2 | $226K | Sell |
16,859
-997
| -6% | -$13.3K | ﹤0.01% | 1091 |
|
|
2023
Q1 | $207K | Sell |
17,856
-21,962
| -55% | -$254K | ﹤0.01% | 1076 |
|
|
2022
Q4 | $326K | Sell |
39,818
-3,918
| -9% | -$32K | ﹤0.01% | 1227 |
|
|
2022
Q3 | $254K | Buy |
43,736
+21,129
| +93% | +$123K | ﹤0.01% | 1266 |
|
|
2022
Q2 | $99.9K | Buy |
22,607
+12,303
| +119% | +$54.4K | ﹤0.01% | 991 |
|
|
2022
Q1 | $94K | Sell |
10,304
-37
| -0.4% | -$338 | ﹤0.01% | 922 |
|
|
2021
Q4 | $212K | Buy |
10,341
+1,406
| +16% | +$28.8K | 0.01% | 822 |
|
|
2021
Q3 | $228K | Buy |
8,935
+1,394
| +18% | +$35.6K | 0.01% | 772 |
|
|
2021
Q2 | $264K | Buy |
+7,541
| New | +$264K | 0.01% | 688 |
|
|
2021
Q1 | – | Sell |
-1,500
| Closed | -$39K | – | 1130 |
|
|
2020
Q4 | $39K | Buy |
+1,500
| New | +$39K | ﹤0.01% | 554 |
|